Cargando…

Influence of pre-transplant minimal residual disease on prognosis after Allo-SCT for patients with acute lymphoblastic leukemia: systematic review and meta-analysis

BACKGROUND: This meta-analysis was performed to explore the impact of minimal residual disease (MRD) prior to transplantation on the prognosis for patients with acute lymphoblastic leukemia (ALL). METHODS: A systematic search of PubMed, Embase, and the Cochrane Library was conducted for relevant stu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shen, Zhenglei, Gu, Xuezhong, Mao, Wenwen, Yin, Liefen, Yang, Ling, Zhang, Zhe, Liu, Kunmei, Wang, Lilan, Huang, Yunchao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6056932/ https://www.ncbi.nlm.nih.gov/pubmed/30037340 http://dx.doi.org/10.1186/s12885-018-4670-5

Ejemplares similares

Characterization of microRNA expression profiles by deep sequencing of small RNA libraries in leukemia patients from Naxi ethnic
por: Shen, Zhenglei, et al.
Publicado: (2019)

Editorial: Strengths and Challenges of Allo-SCT in the Modern Era
por: Malagola, Michele, et al.
Publicado: (2022)

In leukemia, knock-down of the death inducer-obliterator gene would inhibit the proliferation of endothelial cells by inhibiting the expression of CDK6 and CCND1
por: Cao, Honghua, et al.
Publicado: (2022)

Fatal H1N1 influenza infection in an allo-SCT recipient
por: Rozovski, U, et al.
Publicado: (2010)

Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia
por: Kruse, Aaron, et al.
Publicado: (2020)

Allo-SCT for multiple myeloma: a review of outcomes at a single transplant center
por: Bensinger, W, et al.
Publicado: (2012)

Outcomes of Allogeneic Stem Cell Transplant (allo-SCT) Recipients in the Era of Newer Antifungal Agents
por: Shah, Nishi, et al.
Publicado: (2014)

Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances
por: Della Starza, Irene, et al.
Publicado: (2019)

Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia: Egyptian Experience
por: Ibrahim, Rasha Ibrahim, et al.
Publicado: (2022)

What is known about palliative care in adult patients with allogeneic stem cell transplantation (allo-SCT)?
por: Simon, Steffen T., et al.
Publicado: (2021)

Current Strategies for the Detection of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia
por: Rocha, Juliana Maria Camargos, et al.
Publicado: (2016)

Sources of error in measurement of minimal residual disease in childhood acute lymphoblastic leukemia
por: Latham, Sue, et al.
Publicado: (2017)

Minimal Residual Disease in Acute Lymphoblastic Leukemia: Current Practice and Future Directions
por: Contreras Yametti, Gloria Paz, et al.
Publicado: (2021)

Optimizing Molecular Minimal Residual Disease Analysis in Adult Acute Lymphoblastic Leukemia
por: Della Starza, Irene, et al.
Publicado: (2023)

Rapid Recovery from Chronic PRCA by MSC Infusion in Patient after Major ABO-Mismatched alloSCT
por: Sergeevicheva, Vera, et al.
Publicado: (2012)

NKp46 expression on NK cells as a prognostic and predictive biomarker for response to allo-SCT in patients with AML
por: Chretien, Anne-Sophie, et al.
Publicado: (2017)

The utility of multiparametric flow cytometry for the detection of minimal residual disease in acute lymphoblastic leukemia
por: Cunha, Fernanda Gonçalves Pereira, et al.
Publicado: (2012)

Minimal residual disease in acute lymphoblastic leukemia: technical aspects and implications for clinical interpretation
por: Kim, In-Suk
Publicado: (2020)

Circulating microRNAs as minimal residual disease biomarkers in childhood acute lymphoblastic leukemia
por: Rzepiel, Andrea, et al.
Publicado: (2019)

A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT
por: Tran, Misha C., et al.
Publicado: (2022)

Transcriptome Analysis of Minimal Residual Disease in Subtypes of Pediatric B Cell Acute Lymphoblastic Leukemia
por: Sitthi-amorn, Jitsuda, et al.
Publicado: (2015)

Proposal for the standardization of flow cytometry protocols to detect minimal residual disease in acute lymphoblastic leukemia
por: Ikoma, Maura Rosane Valério, et al.
Publicado: (2015)

Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia
por: O’Connor, David, et al.
Publicado: (2018)

Testing for minimal residual disease in adults with acute lymphoblastic leukemia in Europe: a clinician survey
por: Pigneux, Arnaud, et al.
Publicado: (2018)

Minimal residual disease in childhood B Lymphoblastic Leukemia and its correlation with other risk factors
por: Meraj, Fatima, et al.
Publicado: (2020)

P371: PONATINIB AS A PROPHYLACTIC OR PRE-EMPTIVE STRATEGY TO PREVENT CYTOLOGICAL RELAPSE AFTER ALLO-SCT IN PATIENTS WITH PH POS ALL TRANSPLANTED IN COMPLETE CYTOLOGICAL REMISSION
por: Candoni, Anna, et al.
Publicado: (2023)

Comparison of haplo-SCT and chemotherapy for young adults with standard-risk Ph-negative acute lymphoblastic leukemia in CR1
por: Lv, Meng, et al.
Publicado: (2020)

Can allo-SCT with RIC cure ATLL? Long-term survivors with excellent PS and with heterogenous HTLV-1 proviral load level
por: Uike, Naokuni, et al.
Publicado: (2011)

Minimal residual disease detection in Tunisian B-acute lymphoblastic leukemia based on immunoglobulin gene rearrangements
por: Besbes, S., et al.
Publicado: (2017)

Validation of Minimal Residual Disease as Surrogate Endpoint for Event-Free Survival in Childhood Acute Lymphoblastic Leukemia
por: Galimberti, Stefania, et al.
Publicado: (2018)

TFDP3 confers chemoresistance in minimal residual disease within childhood T-cell acute lymphoblastic leukemia
por: Chu, Ming, et al.
Publicado: (2016)

Clinical Significance of Minimal Residual Disease at the End of Remission Induction Therapy in Childhood Acute Lymphoblastic Leukemia
por: Jovanovska, Aleksandra, et al.
Publicado: (2019)

Chimeric Antigens Receptor T Cell Therapy Improve the Prognosis of Pediatric Acute Lymphoblastic Leukemia With Persistent/Recurrent Minimal Residual Disease in First Complete Remission
por: Hu, Guan-hua, et al.
Publicado: (2022)

CAR-T bridging to allo-HSCT as a treatment strategy for relapsed adult acute B-lymphoblastic leukemia: a case report
por: Wen, Shupeng, et al.
Publicado: (2018)

Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913
por: Chiaretti, Sabina, et al.
Publicado: (2020)

Prognostic Significance and Treatment Implications of Minimal Residual Disease Studies in Philadelphia-Negative Adult Acute Lymphoblastic Leukemia
por: Spinelli, Orietta, et al.
Publicado: (2014)

Clinicians’ Perspectives on Cure in Adult Patients with Acute Lymphoblastic Leukemia with Minimal Residual Disease: A Delphi Study
por: Gidman, Wendy, et al.
Publicado: (2019)

P366: ARE MINIMAL RESIDUAL DISEASE MEASUREMENTS AFTER CONSOLIDATION THERAPY USEFUL IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA?
por: Stutterheim, Janine, et al.
Publicado: (2023)

P390: ALLO-HSCT OR CHEMOTHERAPY FOR B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA IN THE FIRST COMPLETE REMISSION: IMPACT OF MRD AND IKZF1
por: Deng, Shiyu, et al.
Publicado: (2023)

Improving the Identification of High Risk Precursor B Acute Lymphoblastic Leukemia Patients with Earlier Quantification of Minimal Residual Disease
por: Karsa, Mawar, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_vdecdnh7ibd8e0nfchndf3nqau